Abstract
Bevacizumab (Avastin) is a humanized anti–vascular endothelial growth factor (VEGF) monoclonal antibody that is FDA-approved for first-line therapy in
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have